RJT
TEVA icon

Raymond James Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Raymond James Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$188K Sell
10,434
-393
-4% -$6.88K ﹤0.01% 1256
2024
Q2 		$176K Buy
10,827
+42
+0.4% +$647 ﹤0.01% 1203
2024
Q1 		$152K Buy
+10,785
New +$136K ﹤0.01% 1211
2023
Q2 		– Sell
-13,377
Closed -$118K – 1213
2023
Q1 		$118K Buy
13,377
+534
+4% +$5.28K ﹤0.01% 1114
2022
Q4 		$117K Hold
12,843
– – ﹤0.01% 1093
2022
Q3 		$104K Sell
12,843
-15,600
-55% -$138K ﹤0.01% 1035
2022
Q2 		$214K Sell
28,443
-1,526
-5% -$13.3K 0.01% 979
2022
Q1 		$281K Sell
29,969
-4,433
-13% -$37K 0.01% 919
2021
Q4 		$276K Sell
34,402
-11,091
-24% -$100K 0.01% 941
2021
Q3 		$443K Hold
45,493
– – 0.01% 665
2021
Q2 		$450K Sell
45,493
-4,300
-9% -$45.5K 0.02% 652
2021
Q1 		$575K Buy
49,793
+2,481
+5% +$28.4K 0.02% 535
2020
Q4 		$457K Sell
47,312
-2,025
-4% -$19.4K 0.02% 577
2020
Q3 		$445K Hold
49,337
– – 0.02% 529
2020
Q2 		$608K Buy
49,337
+7,900
+19% +$89.3K 0.03% 409
2020
Q1 		$372K Buy
41,437
+6,444
+18% +$66K 0.02% 481
2019
Q4 		$343K Sell
34,993
-798
-2% -$7.12K 0.02% 610
2019
Q3 		$246K Buy
35,791
+500
+1% +$3.83K 0.01% 758
2019
Q2 		$326K Buy
35,291
+2,229
+7% +$26.9K 0.02% 592
2019
Q1 		$519K Buy
33,062
+113
+0.3% +$1.99K 0.03% 412
2018
Q4 		$509K Buy
32,949
+1,134
+4% +$23.2K 0.03% 394
2018
Q3 		$685K Buy
31,815
+125
+0.4% +$2.9K 0.04% 354
2018
Q2 		$771K Buy
31,690
+8,840
+39% +$180K 0.05% 316
2018
Q1 		$390K Sell
22,850
-3,095
-12% -$60.4K 0.03% 431
2017
Q4 		$492K Sell
25,945
-6,696
-21% -$101K 0.03% 394
2017
Q3 		$574K Buy
32,641
+8,177
+33% +$184K 0.04% 339
2017
Q2 		$813K Buy
24,464
+3,249
+15% +$101K 0.06% 274
2017
Q1 		$680K Sell
21,215
-2,815
-12% -$96.1K 0.05% 303
2016
Q4 		$871K Sell
24,030
-2,128
-8% -$85K 0.07% 253
2016
Q3 		$1.2M Sell
26,158
-487
-2% -$25.4K 0.1% 193
2016
Q2 		$1.34M Sell
26,645
-1,720
-6% -$91.6K 0.12% 176
2016
Q1 		$1.52M Sell
28,365
-629
-2% -$36.9K 0.14% 148
2015
Q4 		$1.9M Sell
28,994
-1,248
-4% -$77.1K 0.18% 127
2015
Q3 		$1.71M Sell
30,242
-2,392
-7% -$155K 0.19% 119
2015
Q2 		$1.93M Buy
32,634
+1,151
+4% +$71K 0.2% 116
2015
Q1 		$1.96M Sell
31,483
-258
-0.8% -$15K 0.21% 110
2014
Q4 		$1.83M Buy
31,741
+6,866
+28% +$383K 0.2% 122
2014
Q3 		$1.34M Buy
24,875
+1,342
+6% +$71.1K 0.15% 142
2014
Q2 		$1.23M Buy
23,533
+3,935
+20% +$201K 0.14% 148
2014
Q1 		$1.04M Buy
19,598
+8,312
+74% +$384K 0.13% 168
2013
Q4 		$452K Buy
11,286
+3,612
+47% +$142K 0.06% 286
2013
Q3 		$290K Sell
7,674
-366
-5% -$14.3K 0.04% 369
2013
Q2 		$315K Buy
+8,040
New +$313K 0.05% 321

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James Trust's TEVA Position: Q3 2024 in Review

Raymond James Trust reduced its Teva Pharmaceuticals (TEVA) stake by 3.6% in Q3 2024, selling an estimated $6.88K and leaving 10,434 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

Raymond James Trust first reported a position in TEVA in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.96M in Q1 2015. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Raymond James Trust held 10,434 shares of Teva Pharmaceuticals worth $188K as of Q3 2024.
  • Raymond James Trust sold 393 Teva Pharmaceuticals shares in Q3 2024, an estimated $6.88K.
  • Teva Pharmaceuticals made up ﹤0.01% of Raymond James Trust's portfolio in Q3 2024, its #1256 holding.
  • Raymond James Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • Raymond James Trust's Teva Pharmaceuticals position peaked at $1.96M in Q1 2015.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.